JensSConjinAPFransFA, et al. Outcomes of infrainguinal revascularizations with endovascular first strategy in critical limb ischemia. Cardiovasc Intervent Radiol. 2015;38:552–559.
2.
SimonsJPSchanzerA. Lower extremity arterial disease: decision making and medical treatment. In: CronenwettJLJohnstonKW, eds. Rutherford’s Vascular Surgery. 8th ed.Philadelphia, PA: Saunders; 2014:1675–1700.
3.
FagliaEDalla PaolaLClericiG, et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg. 2005;29:620–627.
4.
KatibNThomasSDLennoxAF, et al. An endovascular-first approach to the treatment of critical limb ischemia results in superior limb salvage rates. J Endovasc Ther. 2015;22:473–481.
5.
BradburyAWAdamDJBellJ, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg. 2010;51(5 suppl):18S–31S.
6.
NolanBWDe MartinoRRStoneD, et al; for the Vascular Study Group of New England. Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass. J Vasc Surg. 2011;54:730–736.
7.
JonesDWSchanzerAZhaoY, et al; for the Vascular Study Group of New England. Growing impact of restenosis on the surgical treatment of peripheral arterial disease. J Am Heart Assoc. 2013;2:e000345.
8.
RoyTForbesTWrightGA, et al. Burning bridges: mechanisms and implications of endovascular failure in the treatment of peripheral artery disease. J Endovasc Ther. 2015:22:874–880.
9.
TASC Steering Committee, JaffMRWhiteCJ, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus of the management of peripheral arterial disease (TASC II). J Endovasc Ther. 2015;22:663–677.
10.
AdamDJBeardJBellAW, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934.
11.
MalasMBEnweremNQaziU, et al. Comparison of surgical bypass with angioplasty and stenting of superficial femoral artery disease. J Vasc Surg. 2014;59:129–135.
12.
YahagiKKolodgieFDOtsukaF, et al. Pathophysiology of native coronary, vein graft, an in-stent atherosclerosis. Nat Rev Cardiol. 2016;13:79–98.
KimJSKimJSKimTH, et al. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J. 2010;74:320–326.
15.
FanelliFCannavaleAGazzettiM.Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.
16.
InoueTShinkeTOtakeH, et al. Impact of strut–vessel distance and underlying plaque type on the resolution of acute strut malapposition: serial optimal coherence tomography analysis after everolimus-eluting stent implantation. Int J Cardiovasc Imaging. 2014;30:857–865.
PatelSDZymvragoudakisVSheehanL, et al. Atherosclerotic plaque analysis: a pilot study to predict outcome following lower limb endovascular intervention. Eur J Vasc Endovasc Surg. 2015;50:487–493.
ShammasNW.An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological and procedural factors. Int J Angiol. 2013;22:1–8.
22.
DasTSMcNamaraTGrayB, et al. Primary cryoplasty therapy provides durable support for limb salvage in critical limb ischemia patients with infrapopliteal lesions: 12-month follow up results from the BTK-Chill Trial. J Endovasc Ther. 2009;16(2suppl 2):II19–II30.
23.
SamsonRHShowalterDPLeporeMJr, et al. Cryoplasty therapy of the superficial femoral and popliteal arteries: a reappraisal after 44 months experience. J Vasc Surg. 2008;48:634–637.
PolonskyTLiuKTianLu, et al. High risk plaque in the superficial femoral artery of people with peripheral arterial disease: prevalence and associated clinical characteristics. Atherosclerosis. 2014;237:169–176.
26.
OtsukaFNakanoMLadichE, et al. Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement. Thrombosis. 2012;2012:608593.
27.
MendesBCOderichGSFlemingMD, et al. Clinical significance of embolic events in patients undergoing endovascular femoropopliteal interventions with or without embolic protection devices. J Vasc Surg. 2014;59:359–367.
28.
HiramoriSSogaYTomoiY, et al. Impact of runoff grade after endovascular treatment for femoropopliteal lesions. J Vasc Surg. 2014;59:720–727.
ShammasNWCoinerDShammasGA, et al. Distal embolic event protection using excimer laser ablation in peripheral vascular interventions: results of the DEEP EMBOLI registry. J Endovasc Ther. 2009;16:197–202.
DippelEJMakamPKovachR, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis. JACC Cardiovasc Interv. 2015;8:92–101.
33.
IshiharaYKawasakiMHattoriA, et al. Relationship among coronary plaque compliance, coronary risk factors and tissue characteristics evaluated by integrated backscatter intravascular ultrasound. Cardiovasc Ultrasound. 2012;10:32.
34.
TsetisDMorganRBelliAM.Cutting balloons for the treatment of vascular stenoses. Eur Radiol. 2006;16:1675–1683.
35.
SalehHMGabrAKTawfikMM, et al. Prospective, randomized study of cutting balloon angioplasty versus conventional balloon angioplasty for the treatment of hemodialysis access stenoses. J Vasc Surg. 2014;60:735–740.
36.
RasuliPChennurVSConnollyMJ, et al. Randomized trial comparing the primary patency following cutting versus high-pressure balloon angioplasty for treatment of de novo venous stenoses in hemodialysis arteriovenous fistulae. J Vasc Interv Radiol. 2015;26:1840–1846.e1.
37.
RogersJHLairdJR.Overview of new technologies for lower extremity revascularization. Circulation. 2007;116:2072–2085.
38.
ThindAStraussBTeitelbaumA, et al. A novel method for the measurement of proximal fibrous cap puncture force in chronic total occlusions: the effect of increasing age. EuroIntervention. 2011;6:997–1002.
39.
StraussBHOsherovABRadhakrishnanS, et al. Collagenase total occlusion-1 (CTO-1) trial: a phase 1, dose escalation, safety study. Circulation. 2012;125:522–528.
40.
GoertzDEThindASKarshafianR, et al. In vivo feasibility study of ultrasound potentiated collagenase therapy of chronic total occlusions. Ultrasonics. 2014;54:20–24.
41.
AmannK.Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1599–1605.
42.
MintzGSPopmaJJPichardAD, et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995;91:1959–1965.
43.
MaeharaAMintzGSShimshakTM, et al. Intravascular ultrasound evaluation of JETSTREAM atherectomy removal of superficial calcium in peripheral arteries. EuroIntervention. 2015;11:96–103.
DasTMustaphaJIndesJ, et al. Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremity. The CONFIRM series, a prospective multicenter registry. Catheter Cardiovasc Interv. 2014;83:115–122.
46.
SchroderJ.The mechanical properties of guidewires. Part 1: stiffness and torsional strength. Cardiovasc Intervent Radiol. 1993;16:43–46.
47.
FarbABurkeAPKolodgieFD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108:1701–1706.
48.
FangTD. Ancillary endovascular equipment: catheters, guidewires, and procedural considerations. In: FogartyTJWhiteRA, eds. Peripheral Endovascular Interventions. 3rd ed.New York, NY: Springer Science + Business Media; 2010:165-179.
49.
WalkerC. Guidewire selection for peripheral vascular interventions. Endovascular Today. 2013:80–83.
50.
VarugheseCJRajamanickamASharmaS. Guidewire properties and selection. In: KiniASharmaSNarualJ, eds. Practical Manual of Interventional Cardiology. New York, NY: Springer-Verlag; 2014:55–63.
51.
LiuzzoJPAmbroseJACoppolaJT.Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol. 2005;17:497–502.
52.
StettlerCWandelSAllemannS, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937.
RäberLWohlwendLWiggerM, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819–2828.
55.
ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663–670.
56.
DudaSHBosiersMLammerJ, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
57.
Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
58.
Levant 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
OtsukaFSkakakuraKKazuyukiY, et al. Has our understanding of calcification in human coronary atherosclerosis progressed?Arterioscler Thromb Vasc Biol. 2014;34:724–736.